Skip to content

    Metropolis Healthcare Limited

    METROPOLIS
    Healthcare·14 Aug 2025
    Management Summary

    Metropolis Healthcare reported a robust Q1 FY26, with group revenue up 23.2% and organic revenue growing 13.2%. Profitability saw an uptrend, with organic EBITDA margin at 24.7% and PAT up 21.2%. The company successfully integrated recent acquisitions and announced a new one, while expanding its network and piloting new service lines like basic radiology, positioning for continued growth and margin improvement.

    Highlights

    5

    • Group revenue grew 23.2% YoY, with organic revenue growth at 13.2%, reflecting strong volumes and improved realizations.

    • Organic EBITDA margin expanded 40 bps sequentially to 24.7%, with PAT growing 21.2% YoY to ₹46.2 crores.

    • Core Diagnostics, despite initial low margins, turned positive in Q1 FY26, improving from break-even levels in Q4 FY25.

    • Acquisition of Ambika Diagnostics (₹8 crores revenue, ₹1.8 crores EBITDA in FY25) is expected to be highly accretive from day one, with post-synergy EBITDA projected at ₹3.4 crores.

    • Basic radiology pilot showing encouraging traction, with 20 locations offering full radiology services and 240 offering ECG services, enhancing customer frequency and NPS.

    Concerns

    2

    • Core Diagnostics' low single-digit EBITDA margin profile marginally impacted the consolidated group EBITDA margin, which stood at 23.1%.

    • PAT for Core was negative in Q1, largely due to high depreciation and high-cost interest on a ₹12 crore loan, though this has been refinanced for Q2 improvement.

    What Changed2

    vs Q2 FY26

    Guidance items9 → 6 (-3)Risks discussed3 → 1 (-2)

    Key financials

    Single quarter

    13 metrics
    1. 01Group Revenue—+23.2%YoY
    2. 02Organic Revenue—+13.2%YoY
    3. 03Organic EBITDA₹87.5 Cr+11.9%YoY
    4. 04Organic EBITDA Margin24.7%+0.4%QoQ
    5. 05Group EBITDA Margin23.1%

    Segment breakdown

    Organic B2C
    ₹209 Cr Revenue59% Contribution to Total Revenue37.9 lakhs Patient Volume
    Organic B2B
    10% Revenue Growth14% Contribution to Total Revenue32.8 lakhs Patient Volume
    Group B2C
    19% Revenue Growth56% Contribution to Total Revenue
    Group B2B
    29.0% Revenue Growth
    North Region (Group)
    17% Contribution to Total Revenue
    Tier-1 Towns (Group)
    27% Revenue Growth
    Tier-3 Towns (Group)
    17% Revenue Growth17% Contribution to Total Revenue
    TruHealth Segment (Organic)
    22% Revenue Growth18% Contribution to Overall Revenue
    Specialty Segment (Organic)
    16% Revenue Growth
    List

    Capital allocation

    6
    high confidence
    CategoryHeadline
    Debt

    Debt disclosed

    M&A

    Core Diagnostics

    acquisition · integrated

    M&A

    DAPIC, Dehradun

    acquisition · integrated

    M&A

    Scientific Pathology, Agra

    acquisition · integrated

    M&A

    Ambika Diagnostics, Kolhapur

    acquisition · announced · Consideration ₹NaN (cash)

    Guidance & targets

    6
    CategoryTargetPriority
    Margin
    Core Diagnostics EBITDA Margin
    high single-digit
    		High
    Network Expansion
    New Collection Centers
    400+
    		High
    Market Reach
    Towns Served
    1,000
    		Medium
    B2C Mix
    B2C Contribution to Total Revenue
    60%+
    		Medium
    Volume Growth
    Organic MHL Volume Growth
    7-8%
    		High
    Revenue Per Patient (RPP)
    RPP Increase
    3-5%
    		High

    What to watch in Q2 FY26

    5

    Core Diagnostics EBITDA Margin Improvement

    by end of FY26
    Currentlow single-digit positive
    Targethigh single-digit

    Why it matters

    Core's margin improvement is key to overall group profitability and successful integration of the largest recent acquisition.

    While it is an improvement from the break-even levels of Q4 last year, before we acquired the business, we remain hopeful of bringing the Core's margin profile to high single-digit by the end of the financial year, as integration progresses and synergies begin to reflect the financials.

    Risks & concerns

    1
    RiskSeverity

    Initial low margin profile of acquired entities

    Core Diagnostics' low single-digit EBITDA margin and negative PAT in Q1 FY26 marginally impacted the group's overall profitability, though it is expected to improve. — Management acknowledged

    medium

    Q&A highlights

    8

    “I think on the basic radiology, we will continue to spread it across our centers. And these equipments are not very expensive. These are smaller equipments. A lot of them are on asset-light basis. We are not procuring all of them. It is a combination, I would say. We are evaluating whether higher-end radiology is something worth getting into or not. We do not have a clear answer at this point of time.”

    Analyst sought clarity on the company's long-term strategy for radiology, particularly regarding asset intensity and potential for advanced services, which management indicated is still under evaluation.

    asked by Anshul Agrawal

    2 min read6 chapters

    Detailed Narrative

    01

    Q1 FY26 Performance Overview

    Metropolis Healthcare reported a strong Q1 FY26, with group revenue growing 23.2% year-on-year. Organic revenue growth stood at 13.2%, driven by robust volumes and improved realizations. The company's organic EBITDA margin reached 24.7%, a 40 basis points sequential increase, while organic PAT grew 21.2% year-on-year to ₹46.2 crores, achieving a 13% PAT margin. Group EBITDA margin was 23.1%, impacted by the initial low margins of recent acquisitions.

    02

    Strategic Acquisitions and Integration Progress

    The company is actively integrating three recent acquisitions: Core Diagnostics, DAPIC (Dehradun), and Scientific Pathology (Agra). Core Diagnostics, despite being negative in PAT in Q1 due to high depreciation and interest on a ₹12 crore loan (now refinanced), turned positive with low single-digit EBITDA margins, improving from break-even in Q4 FY25. Management aims to achieve high single-digit EBITDA margins for Core by year-end FY26 through cost synergies. Additionally, Metropolis announced the acquisition of Ambika Diagnostics in Kolhapur for ₹17 crores, which generated ₹8 crores revenue and ₹1.8 crores EBITDA in FY25, with post-synergy EBITDA projected at ₹3.4 crores.

    03

    Network Expansion and B2C/B2B Dynamics

    Metropolis continues its network expansion, adding 80 new collection centers in Q1 FY26 and targeting over 400 additions for the full year, focusing on Tier-2 and Tier-3 towns. The organic B2C business grew 16% year-on-year, driven by 9% patient volume growth and 6% improved test mix and pricing, contributing 59% to organic revenue. The group's B2C contribution was 56%, lower than organic due to Core Diagnostics' B2B focus. Organic B2B revenue grew 10% with 4% patient volume growth and 6% RPP increase.

    04

    New Service Lines and Digital Initiatives

    The company's basic radiology pilot is gaining traction, with 20 locations offering full radiology services (X-ray, sonography, ECG), 36 offering X-ray, and 240 offering ECG. This integrated approach, combining blood diagnostics with non-blood vitals and basic radiology under the TruHealth brand, is enhancing customer engagement and improving RPP. TruHealth contributed 18% to overall revenue in Q1 FY26. Metropolis is also leveraging AI in diagnostics and digital platforms to streamline operations, improve customer experience, and enhance productivity.

    05

    Competitive Landscape and Market Rationality

    Management observed a return to rationality in pricing and a decrease in competitive intensity in the diagnostics market compared to the 2020-2023 period. This shift is attributed to new players realizing the challenges of the industry and a slowdown in funding for companies without proven unit economics. The company believes this increased rationality, combined with operational efficiencies and scale benefits, contributes to improved gross margins across the sector.

    06

    Future Outlook and Strategic Focus

    Metropolis is optimistic about FY25-26, expecting it to be a significant year for organic growth and margin improvement. The company anticipates Q2 to be stronger than Q1, with Q2 and Q4 typically being the best quarters. The strategic focus remains on integrating acquisitions, driving cost synergies, expanding the collection center network, and leveraging scientific depth and innovation to differentiate itself in a market where pricing gaps are narrowing.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.